Groowe Groowe / Newsroom / PFE
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

PFE News

Pfizer Inc.

CGRP Inhibitors Market to Reach US$12.5 Bn by 2033 Expands with Rising Migraine Awareness and Advanced Targeted Therapies - Persistence Market Research

prnewswire.com
AMGN LLY TEVA PFE ABBV

Cutaneous T-Cell Lymphoma Clinical Trial Pipeline Accelerates as 30+ Pharma Companies Rigorously Developing Drugs for Market Entry | DelveInsight

globenewswire.com
SNGX IPHA BMY NKTX AZN MRK TAK NVS GMAB ABBV BIIB CRSP INCY ALKS PFE REGN GILD AMGN

Late-Stage Chronic Kidney Disease Market Analysis Report 2026-2036, Profiles of Key Players - Novartis, Merck & Co, Pfizer, Sanofi, and Johnson & Johnson

globenewswire.com
AMGN FMS DVA ABBV NVS MRK PFE SNY JNJ

Polycystic Kidney Disease Market Analysis Report 2026-2036, Profiles of Key Players - Otsuka Pharmaceutical, Novartis, Pfizer, and Vertex Pharmaceuticals

globenewswire.com
NVS PFE VRTX

Oligometastatic Disease Market Analysis Report 2026-2036, Profiles of Leading Players - Dompe Farmaceutici, Bausch Health, Merck, Pfizer, and Glenmark Pharmaceuticals

globenewswire.com
BDX MRK PFE

Paroxysmal Supraventricular Tachycardia Market Analysis Report 2026-2036, Profiles of Leading Players - Medtronic, Boston Scientific, Abbott Laboratories, Milestone Pharmaceuticals, Sanofi, Pfizer

globenewswire.com
MDT BSX ABT PFE

Hemorrhoids Treatment Market Research Report 2026-2036: Epidemiological Analysis, Treatment and Management, Trends, Clinical Trial Landscape, Pipeline Analysis, Regulatory Landscape

globenewswire.com
PFE JNJ SNY

Laryngeal Cancer Market Research Report 2026-2036, Competitive Analysis of Major Players - Merck & Co., Pfizer, Novartis, and AbbVie

globenewswire.com
MRK PFE ABBV

MRNA Vaccine and Therapeutics Market Research Trends and Forecast Report 2026-2035: Revolutionizing Protein Synthesis, Altering the Biomedical Scene and Paving the Way for Innovative Treatment Options

globenewswire.com
MRNA PFE

Acute Myocardial Infarction Market is Expected to Hit Growth Stride at a CAGR of 13% During the Forecast Period (2026-2036) with New Therapeutic Innovations | DelveInsight

prnewswire.com
NVO BMY JNJ AMGN REGN SNY PFE AZN LLY NVS